Introduction: Topical 5-fluorouracil (5-FU) has been used to treat actinic keratosis for decades.
reviewed weekly for response, and local or systemic side effects. Treatment duration was 12-14 weeks.
Clinical photography was undertaken prior to, during, and after treatment to document response.
Results: We show that there was substantial clinical improvement in the treated skin in our patients. Experienced dermatologists reviewed all the patients, and documented the changes photographically, and by counting lesions. All patients were satisfied with their treatment regimen, and also with the end result;
although two did not complete the treatment regimen due to complications not directly attributable to the treatment.
Conclusion: Topical 5-FU under occlusion (chemowraps) may be a valid treatment option
for large areas of sun-damaged skin with field cancerization changes, due to low systemic and local toxicity, and acceptability to patients. [3, 4] . In this pilot study, we describe our initial experiences with five patients treated with 5-FU chemowraps for diffusely actinic-damaged limbs.
METHODS
All procedures followed were in accordance with the ethical standards of the responsible Patients were informed that topical treatment with 5-FU in this way is an off-label treatment. Five unselected patients with diffuse and heavily UV-damaged limbs consented to treatment. Clinical photography was used to document the lesions and extent of disease prior to, during, and after treatment. Twenty grams of 5-FU was applied to cover each leg, with occlusion using zinc oxide and crepe bandages at each weekly visit. In our patient with arm lesions, 10 g of 5-FU was applied to cover each arm, again under occlusion.
Occlusion was maintained for the week, and patients were reviewed weekly for response, clinical toxicity, and further treatment applications. All patients were reviewed by experienced dermatologists and a specialist nurse. Lesions were noted for their position, and counted, prior to photography. Any lesion suspicious for squamous cell carcinoma (SCC) was excised for histopathology.
Patients were questioned informally at the end of treatment about their satisfaction with their treatment and the outcomes (formal patient satisfaction questionnaires not undertaken). Table 1 shows details of the five patients involved in the 5-FU ''chemowrap'' treatment.
RESULTS
All patients were subjected to weekly reviews with clinical monitoring throughout. Potential side effects of toxicity that were monitored for included neutropenia, mucositis, and diarrhea;
however, no side effects were detected. concern. It is known that the rate-limiting enzyme dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene, deactivates more than 80% of standard oral doses of 5-FU and its prodrug, capecitabine [5] .
True (complete) deficiency of DPD is found in approximately 5% of the population, and drug half-life is prolonged, with accumulation of drug and subsequent toxicity [5] . A further 3-5% of the population have variant mutations in DPYD, which decrease enzymatic activity, and are more susceptible to toxicity [6] . Although our patients only received topical or cryosurgery [7] . It is interesting to speculate that treatment under occlusion with topical 5-FU would be more successful than the standard regimen. Potential advantages of chemowraps compared to some of the other topical treatments include the ability to treat large surface areas and the lack of pain or discomfort so far.
Our experiences with 5-FU chemowraps suggest that this off-label treatment modality is a useful option for patients with large areas of 
